Based on recent data, Madrigal Pharmaceuticals, Inc. (MDGL) shows an Average True Range (ATR) of 24.1 and an Enterprise Value of 4.31B. Its average trading volume over the past 3 months is 336.27K, indicating liquidity. These fundamental metrics provide insight into MDGL's underlying financial health and market activity.
Madrigal Pharmaceuticals, Inc. (MDGL) technical indicators as of December 22, 2025: the SMA 20 is 3.36%, SMA 50 at 16.16%, and SMA 200 at 54.34%. The RSI 14 value is 63.09, suggesting its current momentum. These technical analysis signals help assess MDGL's price trends and potential future movements.
Madrigal Pharmaceuticals, Inc. (MDGL) stock performance overview as of December 22, 2025: The 52-week high is $605 (currently -2.31% below), and the 52-week low is $265 (currently 123.03% above). Over the past year, MDGL's performance is 94.1%, compared to the S&P 500's 12.87% change.
According to market data, Madrigal Pharmaceuticals, Inc. (MDGL) stock's recent performance metrics show that over the last month, MDGL is 5.73%, with a Year-to-Date (YTD) performance of 91.54%. Over the past year, the stock has seen a 94.1% change. These figures summarize MDGL's price movements across various periods, reflecting its historical returns.
According to current financial data, MDGL stock's P/E (TTM) ratio is -46.56, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for MDGL, including P/S (25.43), P/B (18.86), and P/FCF (-42.51), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep